MyMD Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
MyMD Pharmaceuticals, Inc. carries a market capitalization of 4.29M, placing it among publicly traded companies globally. Its enterprise value stands at -8.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 4.29M |
| Enterprise Value | -8.98M |
Share Statistics
MyMD Pharmaceuticals, Inc. currently has 2.37M shares outstanding.
| Shares Outstanding | 2.37M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.03 |
| P/TBV Ratio | -0.34 |
| P/FCF Ratio | -0.38 |
| P/OCF Ratio | -0.38 |
Financial Position
MyMD Pharmaceuticals, Inc. maintains a current ratio of 2.48, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.48 |
| Quick Ratio | 2.26 |
| Debt / Equity | 6.75 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -42.17 |
| Return on Assets (ROA) | -68.51 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -31.03 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
MyMD Pharmaceuticals, Inc.'s stock has declined approximately -94.6131% over the past 52 weeks. The 50-day moving average sits at 2.00, while the 200-day moving average is 5.24.
| Beta (5Y) | N/A |
| 52-Week Price Change | -94.6131% |
| 50-Day Moving Average | 2.00 |
| 200-Day Moving Average | 5.24 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -13.40M, while operating income came in at -13.40M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -13.40M |
| Pretax Income | -17.69M |
| Net Income | -17.69M |
| EBITDA | -13.40M |
| EBIT | -13.40M |
| Earnings Per Share (EPS) | -8.97 |
Balance Sheet
MyMD Pharmaceuticals, Inc. holds 13.07M in cash and equivalents against 25,803.00 in total debt, resulting in a net debt position of -536,026.00. Total book value stands at -123.32M, with working capital of 8.57M providing operational flexibility.
| Cash & Cash Equivalents | 13.07M |
| Total Debt | 25,803.00 |
| Net Debt | -536,026.00 |
| Equity (Book Value) | -123.32M |
| Book Value Per Share | -62.54 |
| Working Capital | 8.57M |
Cash Flow
MyMD Pharmaceuticals, Inc. produced -9.67M in operating cash flow over the past twelve months.
| Operating Cash Flow | -9.67M |
| Capital Expenditures | N/A |
| Free Cash Flow | -9.67M |
| FCF Per Share | -4.90 |
Dividends & Yields
The company's payout ratio of 19.41 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.58 |
| Dividend Yield | N/A |
| Payout Ratio | 19.41 |
| Shareholder Yield | -306.12 |
| FCF Yield | -266.53 |
Stock Splits
MyMD Pharmaceuticals, Inc.'s most recent stock split took place on February 15, 2024 with a 30:1 split ratio.
| Last Split Date | 2/15/2024 |
| Split Ratio | 30:1 |
Scores
MyMD Pharmaceuticals, Inc. posts an Altman Z-Score of -12.92, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.92 |